Assure Tech ( Hangzhou) Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Hangzhou Anxu Biotechnology Co., Ltd. was established in 2008 and is located in the beautiful city of Hangzhou. It is a biopharmaceutical high-tech company that integrates research and development, production, and sales of in vitro diagnostic reagents, POCT instruments, and biological raw materials. Focusing on the research and development, production, and sales of POCT reagents and instruments, while also focusing on the development of biological raw material platforms and product technology reserves, we have formed an integrated layout of the industrial chain from upstream core biological raw materials to diagnostic reagents and instruments. We are one of the few Chinese enterprises in the international market that can compete with multinational in vitro diagnostic giants, and have the competitive strength to develop comprehensively in both domestic and international markets. Since its establishment, the company has always attached great importance to and continuously increased research and development investment. It has been recognized as the "Hangzhou Enterprise High tech Research and Development Center", "National High tech Enterprise", "Provincial High tech Enterprise Research and Development Center", and "National Specialized, Refined, and New Small Giant Enterprise". R&D has always focused on the forefront of the industry and market focus, and has continuously expanded and expanded its fields. Relying on a biological raw material technology platform independently developed and produced by antigen and antibody research and development, as well as a mature immune chromatography and dry biochemical diagnostic technology platform, the company has developed POCT reagents covering eight major fields, including drug testing, infectious disease testing, chronic disease testing, pregnancy testing, tumor testing, myocardial testing, biochemical testing, and allergen testing, as well as related supporting instruments. The products are best-selling in Europe, America, Australia, Asia, Africa More than 150 countries and regions, including Oceania, have been able to quickly update and iterate according to market demand, forming strong market competitiveness. At the same time, the company has focused on laying out a single unit chemiluminescence platform with magnetic bead separation technology and enzymatic chemiluminescence technology as the core, as well as a precision detection platform with molecular diagnosis technology and mass spectrometry detection technology as the core. It is accelerating the industrialization of the chemiluminescence technology platform and precision detection platform. In the future, the company will continue to uphold its mission of "providing excellent products and services for human health", continue to increase investment in the research and development and production of biological raw materials, as well as improve the performance of POCT reagents and instruments, to meet the application needs of different fields, focus on the international and domestic markets, and strive to become a leading enterprise in the domestic and international in vitro diagnostic industry, and make every effort to repay society and investors. |
| Headquarter | Hangzhou |
| Establish Date | 7/4/2008 |
| Listed Code | 688075.SH |
| Listed Date | 11/18/2021 |
| Chairman | Ling Shisheng. |
| CEO | Ling Shisheng. |
| Website | www.diareagent.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
